27 Recruiting Advanced Malignant Solid Neoplasm Phase 2 Clinical Trials
Active phase 2 studies for advanced malignant solid neoplasm enrolling across the USA. Verify eligibility and contact site coordinators.
All Advanced Malignant Solid Neoplasm studiesPhase 2 Studies for Advanced Malignant Solid Neoplasm
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
View Study & Checklist ➔Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
View Study & Checklist ➔Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
View Study & Checklist ➔Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
View Study & Checklist ➔Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
View Study & Checklist ➔A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
📍 UC San Diego Moores Cancer Center — La Jolla, California
View Study & Checklist ➔Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
📍 UC Irvine Health Cancer Center-Newport — Costa Mesa, California
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
📍 OHSU Knight Cancer Institute — Portland, Oregon
View Study & Checklist ➔Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
📍 OHSU Knight Cancer Institute — Portland, Oregon
View Study & Checklist ➔Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
View Study & Checklist ➔Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔